Search research articles
Contact Us
Filters
Showing results (1-10 of 86) with videos related to
Page
of 9
Sort By:
Neural Regeneration Research
|
January 17, 2025
Targeting Wallerian degeneration in glaucoma
Melissa Jöe, Pete A Williams
Drug Design, Development and Therapy
|
June 23, 2026
Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies
Seungsoo Rho, Pete A Williams
The American Journal of Pathology
|
May 29, 2026
Histopathological findings and knowledge gaps in glaucomatous neurodegeneration
Flora Hui, Pete A Williams
European Journal of Ophthalmology
|
February 4, 2026
Vitamins and nutraceuticals in glaucoma research
Flora Hui, Pete A Williams
Neural Regeneration Research
|
May 20, 2024
Pyrroloquinoline quinone: a potential neuroprotective compound for neurodegenerative diseases targeting metabolism
Alessio Canovai, Pete A Williams
Experimental Neurology
|
June 24, 2026
Programmed axon degeneration gene variants in human disease
Eleanor L Hopkins, Pete A Williams
Neural Regeneration Research
|
December 16, 2023
Glycolysis and glucose metabolism as a target for bioenergetic and neuronal protection in glaucoma
Pete A Williams, Robert J Casson
Neural Regeneration Research
|
December 30, 2025
Treating dysfunctional one-carbon metabolism in glaucoma
James R Tribble, Pete A Williams
Discover Oncology
|
October 31, 2022
The prognostic implication of latitude in uveal melanoma: a nationwide observational cohort study of all patients born in Sweden between 1947 and 1989
Gustav Stålhammar, Pete A Williams, Tomas Landelius
Brain : a Journal of Neurology
|
September 7, 2010
Opa1 deficiency in a mouse model of dominant optic atrophy leads to retinal ganglion cell dendropathy
Pete A Williams, James E Morgan, Marcela Votruba
Page
of 9
Search research articles
Search
Showing results (1-10 of 86) with videos related to
Sort By:
Page
of 9
Neural Regeneration Research
|
January 17, 2025
Targeting Wallerian degeneration in glaucoma
Melissa Jöe, Pete A Williams
Drug Design, Development and Therapy
|
June 23, 2026
Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies
Seungsoo Rho, Pete A Williams
The American Journal of Pathology
|
May 29, 2026
Histopathological findings and knowledge gaps in glaucomatous neurodegeneration
Flora Hui, Pete A Williams
European Journal of Ophthalmology
|
February 4, 2026
Vitamins and nutraceuticals in glaucoma research
Flora Hui, Pete A Williams
Neural Regeneration Research
|
May 20, 2024
Pyrroloquinoline quinone: a potential neuroprotective compound for neurodegenerative diseases targeting metabolism
Alessio Canovai, Pete A Williams
Experimental Neurology
|
June 24, 2026
Programmed axon degeneration gene variants in human disease
Eleanor L Hopkins, Pete A Williams
Neural Regeneration Research
|
December 16, 2023
Glycolysis and glucose metabolism as a target for bioenergetic and neuronal protection in glaucoma
Pete A Williams, Robert J Casson
Neural Regeneration Research
|
December 30, 2025
Treating dysfunctional one-carbon metabolism in glaucoma
James R Tribble, Pete A Williams
Discover Oncology
|
October 31, 2022
The prognostic implication of latitude in uveal melanoma: a nationwide observational cohort study of all patients born in Sweden between 1947 and 1989
Gustav Stålhammar, Pete A Williams, Tomas Landelius
Brain : a Journal of Neurology
|
September 7, 2010
Opa1 deficiency in a mouse model of dominant optic atrophy leads to retinal ganglion cell dendropathy
Pete A Williams, James E Morgan, Marcela Votruba
Page
of 9